# LEO 90105 Ointment in Japanese Subjects With Psoriasis

> **NCT01422434** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 676 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LEO 90105 = calcipotriol + betamethasone dipropionate
- **DRUG:** Dovonex® = calcipotriol
- **DRUG:** Rinderon® - DP = betamethasone dipropionate

## Key facts

- **NCT ID:** NCT01422434
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 676 (ACTUAL)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01422434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01422434, "LEO 90105 Ointment in Japanese Subjects With Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01422434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*